Synairgen plc Interim Results For The Six Months Ended 30 June 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A period of transformation with lead programme out-licensed to AstraZeneca and novel assets identified for development

Southampton, UK – 25 September 2014: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 June 2014.

Operational highlights

• Global exclusive licence agreement signed in June with AstraZeneca for SNG001 (inhaled interferon beta) for all respiratory indications. $7.25 million up-front payment and potential development, regulatory and commercial milestones of up to $225 million plus up to mid-teen tiered royalties on future potential sales

• Phase II clinical data published in the American Journal of Respiratory and Critical Care Medicine: “The effect of inhaled interferon-beta on worsening of asthma symptoms caused by viral infections: a randomised trial” in July 2014

• Screening of new development opportunities using Synairgen’s proprietary “Biobank” platform leveraging Synairgen’s world-class founder and KOL respiratory drug discovery and development expertise

Financial highlights

• Upfront payment from AstraZeneca agreement of $7.25M (£4.25 million)

• Research and development expenditure for the period was £1.27 million (H1 2013: £0.68 million)

• Post-tax profit for the period of £1.90 million (H1 2013: loss of £1.06 million) largely due to the upfront payment from the AstraZeneca licensing transaction

• Cash and deposit balances of £6.08 million at 30 June 2014 (30 June 2013: £2.14 million) and increase in such balances for the period of £4.79 million (H1 2013: £0.95 million decrease)

• Post period-end fundraising (July 2014) of £5.3 million (before expenses)

Commenting on this transformational period, Simon Shaw, Chairman of Synairgen, said: “During the period, Synairgen has been focused on signing the right deal for our novel therapeutic, SNG001. We were delighted to announce a global, exclusive development and commercialisation agreement with AstraZeneca in June.

“This transformative deal was major news for our investors and world-leading experts. We delivered a successful fundraise as a result of the deal and are now screening, via our novel Biobank, a number of potentially very exciting respiratory assets to bring into our pipeline.”

-Ends-

For further information, please contact:

Synairgen plc
Tel: + 44 (0) 23 8051 2800
Richard Marsden, Chief Executive Officer
John Ward, Finance Director

FinnCap Tel: + 44 (0) 20 7220 0500
Geoff Nash, Christopher Raggett (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701

Help employers find you! Check out all the jobs and post your resume.

Back to news